CUMYL-PEGACLONE (SGT-151) is a
gamma-carboline based
synthetic cannabinoid that has been sold as a
designer drug
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. D ...
.
The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by
Bristol-Myers Squibb
The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the lar ...
in 2001.
Legal status
Sweden's public health agency classified CUMYL-PEGACLONE as a narcotic substance, on January 18, 2019.
See also
*
5F-CUMYL-PEGACLONE
*
CUMYL-CB-MEGACLONE
*
CUMYL-CH-MEGACLONE
*
CUMYL-BC-HPMEGACLONE-221
*
CUMYL-PINACA
CUMYL-PINACA (also known as SGT-24) is an indazole-3-carboxamide based synthetic cannabinoid. CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with approximately 3x selectivity for CB1, having an EC50 of 0.15nM for human CB1 ...
*
CUMYL-5F-P7AICA
5F-CUMYL-P7AICA (also known as CUMYL-5F-P7AICA or SGT-263) is a pyrrolo ,3-byridine-3-carboxamide based synthetic cannabinoid that has been sold as a designer drug. It was first identified by the EMCDDA in February 2015.
See also
* 5F-A-P7AIC ...
*
UR-12
References
Cannabinoids
Designer drugs
Gamma-Carbolines
{{cannabinoid-stub